



# CompuGroup Medical Quarterly Statement as of September 30, 2024

We create the future of e-health

## NOTICE

Since financial year 2020, CompuGroup Medical has been reporting adjusted key figures for operating income (EBITDA) and earnings per share. These key performance indicators are not defined under the International Financial Reporting Standards (IFRS) and should thus be regarded as supplementary information. The adjusted EBITDA and adjusted earnings per share do not include effects from the acquisition and disposal of major subsidiaries, business units and investments (including effects from the subsequent measurement of contingent purchase price liabilities), write-downs and write-ups on investments, restructuring expenses, effects from the acquisition, disposal and construction of real estate, write-downs and write-ups on owner-occupied real estate, expenses in connection with share-based compensation programs for the Managing Directors, taxes attributable to the above effects and other non-operating effects or one-off effects referring to other periods.

Since the beginning of financial year 2024, the operating segment Consumer & Health Management Systems (CHS) is integrated into the Ambulatory Information Systems (AIS) segment. Prior year figures are restated accordingly for comparison purposes. Unless stated otherwise, all information and explanatory notes in this report refer to the first nine months of 2024 and 2023, i.e. the nine-month period from January 1 to September 30, and all percentage changes refer to the respective year-on-year comparison. Due to rounding, totals and percentages presented in this report may not add up precisely to the totals provided.

## Financial key figures

kEUR	Q3 2024	Q3 2023	Change	01.01.- 30.09.2024	01.01.- 30.09.2023	Change
Revenues	283,444	285,718	- 1 %	845,297	880,739	- 4 %
Recurring Revenues	213,476	202,241	+ 6 %	636,914	602,824	+ 6 %
One-Time Revenues	69,968	83,477	- 16 %	208,383	277,915	- 25 %
Organic Growth in %	- 1 %	1 %	- 2 ppt	- 4 %	8 %	- 12 ppt
EBITDA adjusted	54,946	62,150	- 12 %	169,200	195,243	- 13 %
in % of revenues	19 %	22 %	- 3 ppt	20 %	22 %	- 2 ppt
EPS adjusted (EUR) - diluted	0.35	0.43	- 19 %	1.16	1.50	- 23 %
Free cash flow	17,308	7,753	+ 123 %	55,995	90,287	- 38 %
Number of shares outstanding ('000)				51,735	52,235	- 1 %

## EARNINGS DEVELOPMENT IN THE GROUP

kEUR	Q3 2024	Q3 2023	01.01.-30.09.2024	01.01.-30.09.2023
Revenues	283,444	285,718	845,297	880,739
Other income	7,659	4,277	21,387	19,557
Capitalized in-house services	7,334	8,456	24,296	27,381
Expenses for goods and services purchased	-52,627	-53,067	-158,833	-159,106
Personnel expenses	-139,935	-139,401	-416,975	-421,154
Other expenses	-51,791	-47,627	-145,187	-152,743
<b>EBITDA</b>	<b>54,084</b>	<b>58,356</b>	<b>169,985</b>	<b>194,674</b>
in % of revenues	19.1%	20.4%	20.1%	22.1%
<b>EBIT</b>	<b>26,752</b>	<b>31,602</b>	<b>87,687</b>	<b>115,506</b>
in % of revenues	9.4%	11.1%	10.4%	13.1%
<b>EBT</b>	<b>12,273</b>	<b>24,796</b>	<b>58,281</b>	<b>91,401</b>
in % of revenues	4.3%	8.7%	6.9%	10.4%
<b>Consolidated net income</b>	<b>8,591</b>	<b>16,774</b>	<b>40,797</b>	<b>62,357</b>
in % of revenues	3.0%	5.9%	4.8%	7.1%

Revenues decreased by 35 mEUR (- 4 %) to 845 mEUR for the **first nine months of 2024**. Organic growth in this period was - 4 % year-on-year. The revenue decline was attributable to the development of one-time revenues which declined by 70 mEUR (- 25 %) to 208 mEUR. Recurring revenues grew by 34 mEUR (+ 6 %) to 637 mEUR, thus accounting for 75 % of total revenues.

Revenues decreased slightly (- 1 %) to 283 mEUR (prior year: 286 mEUR) for the **third quarter**. Organic growth in this period was - 1 % year-on-year. The revenue decline was attributable to the development of one-time revenues which declined by 14 mEUR (- 16 %) to 70 mEUR. Recurring revenues grew by 11 mEUR (+ 6 %), thus accounting for 75 % of total revenues.

Other income increased by 2 mEUR for the **first nine months of 2024**. The increase of 3 mEUR in the **third quarter** is mainly due to compensation payments of an insurance claim.

The main developments in operating expenses were:

- In the **first nine months of 2024**, expenses for goods and services purchased remained at 159 mEUR compared to the reference period of last year. In the **third quarter**, expenses for goods and services purchased also remained stable at 53 mEUR compared to prior year.

- Personnel expenses decreased from 421 mEUR in 2023 to 417 mEUR in the **first nine months of 2024**. The decrease was mainly due to savings resulting from the restructuring measures initiated in the fourth quarter of the prior year and decreased headcount. In the **third quarter**, personnel expenses increased by 1 mEUR to 140 mEUR compared to the prior year (139 mEUR).
- In the **first nine months of 2024**, other expenses including impairment losses on financial assets and contract assets decreased from 153 mEUR in 2023 to 145 mEUR in 2024, mainly due to general cost measures, as well as lower law and consultancy fees. In the **third quarter**, other expenses including impairment losses on financial assets and contract assets slightly increased from 48 mEUR to 52 mEUR.
- Adjusted group EBITDA was derived from reported EBITDA as shown below:

kEUR	Q3 2024	Q3 2023	01.01.-30.09.2024	01.01.-30.09.2023
<b>EBITDA reported</b>	<b>54,084</b>	<b>58,356</b>	<b>169,985</b>	<b>194,674</b>
Adjustments:				
M&A transactions	-143	632	37	2,919
Share-based option programs	-662	-1,020	35	-7,357
Restructuring program expenses	-599	0	-1,123	0
Other non-operative, extraordinary or one-time effects	2,266	4,182	266	5,007
<b>EBITDA adjusted</b>	<b>54,946</b>	<b>62,150</b>	<b>169,200</b>	<b>195,243</b>
Adjusted EBITDA margin in %	19.4%	21.8%	20.0%	22.2%

Adjusted earnings before interest, taxes, depreciation and amortization (adjusted group EBITDA) for the **first nine months of 2024** amounted to 169 mEUR (prior year: 195 mEUR) with an adjusted EBITDA margin of 20 % (prior year: 22 %).

Adjusted earnings before interest, taxes, depreciation and amortization (adjusted group EBITDA) for the **third quarter** amounted to 55 mEUR (prior year: 62 mEUR) with an adjusted EBITDA margin of 19 % (prior year: 22 %).

In the **first nine months of 2024**, financial expenses increased from 25 mEUR in 2023 to 31 mEUR. In the **third quarter**, financial expenses increased from 7 mEUR to 14 mEUR. The reason for the increase was mainly due to the higher utilization of bank loans and the increased interest rates compared to the prior year.

Free cash flow amounted to 56 mEUR in the **first nine months of 2024** compared to 90 mEUR in the reference period of prior year, mainly due to lower one-time revenues. The development of free cash flow in the **third quarter** was supported by improved working capital management and amounted to 17 mEUR (prior year: 8 mEUR).

Adjusted earnings per share were as follows:

kEUR	Q3 2024	Q3 2023	01.01.- 30.09.2024	01.01.- 30.09.2023
<b>Consolidated net income for the period</b>	<b>8,591</b>	<b>16,774</b>	<b>40,797</b>	<b>62,357</b>
of which: allocated to non-controlling interests	- 30	826	- 273	537
<b>Consolidated net income of the period (allocated to shareholders of the parent company)</b>	<b>8,621</b>	<b>15,948</b>	<b>41,070</b>	<b>61,820</b>
Adjustments:				
M&A transactions	6,240	6,841	19,273	21,582
Share-based option programs	- 662	- 1,020	35	- 7,357
Restructuring program expenses	- 599	0	- 1,123	0
Other non-operative, extraordinary or one-time effects	8,150	2,831	6,014	7,256
Taxes attributable to these effects	- 3,309	- 2,063	- 4,756	- 4,854
<b>Adjusted consolidated net income for the period (allocated to shareholders of the parent company)</b>	<b>18,441</b>	<b>22,536</b>	<b>60,513</b>	<b>78,448</b>
<b>Adjusted undiluted earnings per share (in EUR)</b>	<b>0.36</b>	<b>0.43</b>	<b>1.17</b>	<b>1.50</b>
<b>Adjusted diluted earnings per share (in EUR)</b>	<b>0.35</b>	<b>0.43</b>	<b>1.16</b>	<b>1.50</b>
weighted average of outstanding shares acc. to IAS 33 - undiluted ('000)	51,707	52,235	51,920	52,235
weighted average of outstanding shares acc. to IAS 33 - diluted ('000)	52,429	52,239	52,139	52,268

# EARNINGS DEVELOPMENT OF THE BUSINESS SEGMENTS

## Ambulatory Information Systems (AIS)

mEUR	Q3 2024	Q3 2023*	Change	01.01.- 30.09.2024	01.01.- 30.09.2023*	Change
Revenues to third parties	172.8	171.7	+ 1 %	510.8	548.4	- 7 %
Recurring Revenues	133.0	127.0	+ 5 %	394.9	379.0	+ 4 %
Recurring revenue share in %	77 %	74 %	+ 3 ppt	77 %	69 %	+ 8 ppt
Organic Growth in %	0 %	-5 %	+ 5 ppt	-7 %	7 %	- 14 ppt
EBITDA adjusted	40.4	41.8	- 3 %	123.2	144.0	- 14 %
in % of revenues	23 %	24 %	- 1 ppt	24 %	26 %	- 2 ppt

\* In 2024, the prior operating segment Consumer & Health Management Systems (CHS) was integrated into the Ambulatory Information Systems Segment (AIS), and some minor profit centers were based on the current structure.

Revenues in the **first nine months of 2024** decreased by 7 % year-on-year to 511 mEUR. The revenue decline was attributable to the development of one-time revenues which declined by 53 mEUR (- 32 %) to 116 mEUR, mainly due to higher one-time revenues related to Telematics Infrastructure in the first half of 2023. Recurring revenues grew by 16 mEUR (+ 4 %) to 395 mEUR, thus accounting for 77 % of segment revenues. Adjusted EBITDA decreased by 14 % to 123 mEUR.

Revenues in the **third quarter** increased by 1 % year-on-year to 173 mEUR. Revenue growth was attributable to the development of recurring revenues which increased by 6 mEUR (+ 5 %), thus now accounting for 77 % of segment revenues. One-time revenues declined by 5 mEUR (- 11 %) against strong prior-year one-offs especially in the dental and US business. Adjusted EBITDA decreased by 3 % to 40 mEUR.

## Hospital Information Systems (HIS)

mEUR	Q3 2024	Q3 2023	Change	01.01.- 30.09.2024	01.01.- 30.09.2023	Change
Revenues to third parties	76.6	79.6	- 4 %	232.5	228.8	+ 2 %
Recurring Revenues	56.6	52.2	+ 8 %	169.6	155.1	+ 9 %
Recurring revenue share in %	74 %	66 %	+ 8 ppt	73 %	68 %	+ 5 ppt
Organic Growth in %	-4 %	14 %	- 18 ppt	1 %	12 %	- 11 ppt
EBITDA adjusted	9.7	11.7	- 17 %	26.2	25.4	+ 3 %
in % of revenues	13 %	15 %	- 2 ppt	11 %	11 %	+ 0 ppt

In the **first nine months of 2024**, revenues increased by 2 % to 232 mEUR. Revenue growth was attributable to the development of recurring revenues which increased by 14 mEUR (+ 9 %) to 170 mEUR, corresponding to 73 % of total revenues. The one-time revenues declined by 11 mEUR (- 15 %) to 63 mEUR, mainly due to higher project revenues in Germany and Switzerland in the prior year period. Adjusted EBITDA increased to 26 mEUR, up 3 % year-on-year.

In the **third quarter**, revenues decreased by 4 % to 77 mEUR. The revenue decline was attributable to the development of one-time revenues which declined by 7 mEUR (- 27 %) to 20 mEUR, mainly due to higher project rollouts in Germany, Switzerland and Poland as well as regulatory initiatives in rehab clinics in the prior year. Recurring revenues increased by 4 mEUR (+ 8 %) to 57 mEUR. Adjusted EBITDA decreased by 17 % to 10 mEUR mainly due to continued investment in major projects and next generation technology.

#### Pharmacy Information Systems (PCS)

mEUR	Q3 2024	Q3 2023	Change	01.01.- 30.09.2024	01.01.- 30.09.2023	Change
Revenues to third parties	34.0	34.5	- 1 %	102.0	103.5	- 1 %
Recurring Revenues	23.9	23.0	+ 4 %	72.4	68.7	+ 6 %
Recurring revenue share in %	70 %	67 %	+ 3 ppt	71 %	66 %	+ 5 ppt
Organic Growth in %	-1 %	8 %	- 9 ppt	-1 %	8 %	- 9 ppt
EBITDA adjusted	12.4	11.1	+ 12 %	37.2	34.2	+ 9 %
in % of revenues	36 %	32 %	+ 4 ppt	36 %	33 %	+ 3 ppt

In the **first nine months of 2024**, revenues declined by 1 % to 102 mEUR. The revenue decline was attributable to the development of one-time revenues which declined by 5 mEUR (- 15 %) to 30 mEUR, mainly due to higher hardware revenues in Italy in the prior year period. Recurring revenues increased by 4 mEUR (+ 6 %) to 72 mEUR compared to the same period of the prior year. Adjusted EBITDA was at 37 mEUR, up 9 % on the prior-year period.

Revenues in the **third quarter** decreased to 34 mEUR, down 1 % on the prior year's quarter. The revenue decline was attributable to the development of one-time revenues which declined by 1 mEUR (- 12 %) to 10 mEUR, mainly due to higher hardware revenues in Italy in the prior year period. Recurring revenues increased by 1 mEUR (+ 4 %) to 24 mEUR, representing 70 % of total revenues. Adjusted EBITDA amounted to 12 mEUR and was thus 12 % above the prior year figure, predominantly due to strong Hardware sales in Germany and continuous improvement of costs.

## Other segments and consolidation

mEUR	Q3 2024	Q3 2023*	Change	01.01.- 30.09.2024	01.01.- 30.09.2023*	Change
EBITDA adjusted	- 7.5	- 2.4	- 213 %	- 17.4	- 8.4	- 108 %

\* In 2024, some minor profit centers were reallocated between the segments, so the prior year figures have been updated based on the current structure.

Adjusted EBITDA includes the Group Functions cost, e.g. Group Information Technology, Finance, Human Resources and further functions.

In the **first nine months of 2024**, adjusted EBITDA amounted to - 17 mEUR, 108 % below prior year's figure, which is mainly due to the release of provisions in prior year period.

Adjusted EBITDA in the **third quarter** decreased to - 7 mEUR compared to prior year's figure. This was mainly due to the release of provisions in prior year quarter.

## Staff development

Staff development	Sep 30, 2024	Sep 30, 2023	Dec 31, 2023
Number of employees (HC)	8,773	9,288	9,199
thereof from acquisitions as at time of acquisition	98	164	181
Full-time equivalent (FTE)*	8,412	8,904	8,810

\* FTE: Indicates for a number of real jobs with different time models the number of notional full-time jobs with the same work capacity.

# Interim Statement of Financial Position

as of September 30, 2024

## Assets

kEUR	Sep 30, 2024	Sep 30, 2023	Dec 31, 2023
<b>Non-current assets</b>			
Intangible assets	1,342,812	1,332,168	1,309,857
Property, plant and equipment	114,317	108,272	108,405
Right-of-use assets	53,444	49,151	57,294
Investments in associates and joint ventures (valued at-equity)	15,323	7,479	15,249
Other investments	617	3,163	615
Finance lease receivables	12,866	14,605	14,189
Other financial assets	3,051	3,626	3,333
Derivative financial instruments	8,803	35,881	16,840
Other non-financial assets	1,699	1,200	1,700
Deferred taxes	2,586	2,353	2,632
	<b>1,555,518</b>	<b>1,557,898</b>	<b>1,530,114</b>
<b>Current assets</b>			
Inventories	18,609	21,196	18,881
Trade receivables	170,060	176,512	175,464
Finance lease receivables	8,950	8,591	8,538
Contract assets	31,283	32,713	27,089
Other financial assets	5,006	3,223	7,796
Derivative financial instruments	8	804	1,161
Other non-financial assets	40,563	33,471	27,831
Income tax receivables	28,416	35,231	37,752
Cash & cash equivalents	74,973	66,586	64,461
	<b>377,868</b>	<b>378,327</b>	<b>368,973</b>
Assets qualified as held for sale	0	0	856
	<b>1,933,386</b>	<b>1,936,225</b>	<b>1,899,943</b>

# Interim Statement of Financial Position

as of September 30, 2024

## Shareholder's Equity and Liabilities

kEUR	Sep 30, 2024	Sep 30, 2023	Dec 31, 2023
<b>Equity</b>			
Subscribed capital	53,735	53,735	53,735
Treasury shares	- 119,847	- 105,205	- 105,205
Reserves	700,313	751,382	719,148
<b>Capital and reserves allocated to the shareholders of the parent company</b>	<b>634,201</b>	<b>699,912</b>	<b>667,678</b>
Non-controlling interests	1,041	1,175	1,594
	<b>635,242</b>	<b>701,087</b>	<b>669,272</b>
<b>Non-current liabilities</b>			
Provisions for post-employment benefits and other non-current provisions	34,922	33,852	34,940
Liabilities to banks	743,472	689,202	704,168
Contract liabilities	3,453	15,033	4,578
Purchase price liabilities	22,466	10,800	10,210
Lease liabilities	32,994	34,205	36,829
Other financial liabilities	55	200	87
Other non-financial liabilities	24	47	25
Deferred taxes	95,134	112,129	93,007
	<b>932,520</b>	<b>895,468</b>	<b>883,844</b>
<b>Current liabilities</b>			
Liabilities to banks	55,236	25,116	6,252
Contract liabilities	107,173	91,070	62,567
Purchase price liabilities	2,225	6,434	3,963
Trade payables	76,089	87,782	93,006
Income tax liabilities	26,634	30,518	48,899
Other provisions	48,012	56,269	77,376
Derivative financial instruments	34	487	194
Lease liabilities	20,005	14,532	19,606
Other financial liabilities	5,965	4,674	5,910
Other non-financial liabilities	24,251	22,788	27,541
	<b>365,624</b>	<b>339,670</b>	<b>345,314</b>
Liabilities related to assets held for sale	0	0	1,513
	<b>1,933,386</b>	<b>1,936,225</b>	<b>1,899,943</b>

# Interim Income Statement

for the reporting period of January 1 - September 30, 2024

	Q3 2024	Q3 2023	01.01.-30.09.2024	01.01.-30.09.2023	2023
Revenues	283,444	285,718	845,297	880,739	1,187,663
Capitalized inhouse services	7,334	8,456	24,296	27,381	40,139
Other income	7,659	4,277	21,387	19,557	28,868
Expenses for goods and services purchased	-52,627	-53,067	-158,833	-159,106	-222,747
Personnel expenses	-139,935	-139,401	-416,975	-421,154	-590,414
Net impairment losses on financial and contract assets	-1,912	-1,696	-4,729	-5,400	-11,438
Other expenses	-49,879	-45,931	-140,458	-147,343	-202,311
<b>Earnings before interest, taxes, depreciation and amortization (EBITDA)</b>	<b>54,084</b>	<b>58,356</b>	<b>169,985</b>	<b>194,674</b>	<b>229,760</b>
Depreciation of property, plant and equipment and right-of-use assets	-10,608	-10,563	-31,300	-30,063	-39,835
<b>Earnings before interest, taxes and amortization (EBITA)</b>	<b>43,476</b>	<b>47,793</b>	<b>138,685</b>	<b>164,611</b>	<b>189,925</b>
Amortization of intangible assets	-16,724	-16,191	-50,998	-49,105	-75,963
thereof from purchase price allocations	-11,149	-10,677	-32,969	-32,425	-43,541
<b>Earnings before interest and taxes (EBIT)</b>	<b>26,752</b>	<b>31,602</b>	<b>87,687</b>	<b>115,506</b>	<b>113,962</b>
Result from companies accounted for using the equity method	0	0	0	0	623
Financial income	-757	33	1,242	529	2,820
Financial expenses	-13,722	-6,839	-30,648	-24,634	-44,169
Net impairment losses on financial assets	0	0	0	0	-564
<b>Earnings before taxes (EBT)</b>	<b>12,273</b>	<b>24,796</b>	<b>58,281</b>	<b>91,401</b>	<b>72,672</b>
Income taxes for the period	-3,682	-8,022	-17,484	-29,044	-25,800
<b>Consolidated net income for the period</b>	<b>8,591</b>	<b>16,774</b>	<b>40,797</b>	<b>62,357</b>	<b>46,872</b>
of which: allocated to shareholders of the parent company	8,621	15,948	41,070	61,820	45,916
of which: allocated to non-controlling interests	-30	826	-273	537	956
<b>Earnings per share</b>					
undiluted (EUR)	0.17	0.31	0.79	1.18	0.88
diluted (EUR)	0.16	0.31	0.79	1.18	0.88

# Cash Flow Statement

as of September 30, 2024

KEUR	Q3 2024	Q3 2023	01.01.- 30.09.2024	01.01.- 30.09.2023	2023
Consolidated net income for the period	8,591	16,774	40,797	62,357	46,872
Depreciation of property, plant and equipment and right-of-use assets and amortization of intangible assets	27,333	26,754	82,298	79,168	115,798
Earnings on sale of fixed assets	19	-73	-213	-25	-1,035
Change in provisions (including income tax liabilities)	-8,947	4,014	-52,892	-4,856	33,409
Change in derivative financial instruments	12,358	-889	9,015	1,983	18,425
Deferred tax income/expense	1,111	20	-953	6	-15,297
Other non-cash earnings/ expenditures	3,583	-3,943	1,523	-5,094	-9,552
	<b>44,048</b>	<b>42,657</b>	<b>79,575</b>	<b>133,539</b>	<b>188,620</b>
Change in inventories	-659	898	300	8,247	10,582
Change in trade receivables and other receivables	-2,849	-5,409	4,141	6,835	11,119
Change in income tax receivables	4,166	8,024	9,309	13,342	10,844
Change in other receivables	1,674	8,155	-9,664	-7,946	-6,554
Change in trade payables	4,385	2,240	-17,047	-34,763	-21,075
Change in contract liabilities	-22,288	-26,785	41,806	23,765	-14,738
Change in other liabilities	2,449	-7,976	-4,171	-6,797	730
<b>Operating cash flow</b>	<b>30,927</b>	<b>21,804</b>	<b>104,249</b>	<b>136,222</b>	<b>179,528</b>
Cash outflow for capital expenditure for intangible assets	-8,889	-10,310	-29,239	-32,373	-48,879
Cash inflow from disposals of property, plant and equipment	14	68	353	312	1,325
Cash outflow for capital expenditure for property, plant and equipment	-4,744	-3,809	-19,368	-13,874	-18,973
Net cash outflow for company acquisitions (less acquired cash and cash equivalents and prepayments in prior periods)	-3,383	-1,266	-41,676	-28,719	-34,951
Cash outflow for acquisitions from prior periods	-2,000	0	-3,924	-12,693	-15,287
Cash inflow from the disposal of subsidiaries and business units	687	0	4,949	0	0
Cash outflow for capital expenditures for joint ventures and other equity investments	0	-180	-313	-180	-7,562
<b>Cash flow from investing activities</b>	<b>-18,315</b>	<b>-15,497</b>	<b>-89,218</b>	<b>-87,527</b>	<b>-124,327</b>
Buyback of treasury shares	0	0	-14,642	0	0
Dividend paid	0	0	-51,735	-26,117	-26,117
Capital paid to non-controlling interests	-279	-211	-279	-211	-211
Acquisition of additional shares from non-controlling interests	0	-4,500	0	-8,875	-4,329
Downpayment of lease liabilities	-6,182	-6,589	-19,036	-18,886	-25,819
Cash inflow from borrowing of loans	-8,673	-33,981	81,227	10,021	480,000
Cash outflow from the repayment of loans	116	47,155	0	-27,485	-504,211
<b>Cash flow from financing activities</b>	<b>-15,018</b>	<b>1,874</b>	<b>-4,465</b>	<b>-71,553</b>	<b>-80,687</b>
Cash and cash equivalents at the beginning of the period	77,757	58,044	64,461	90,517	90,517
<b>Change in cash and cash equivalents</b>	<b>-2,406</b>	<b>8,181</b>	<b>10,566</b>	<b>-22,858</b>	<b>-25,486</b>
Changes due to exchange rate fluctuations	-377	361	-53	-1,073	-570
<b>Cash and cash equivalents at the end of the period</b>	<b>74,974</b>	<b>66,586</b>	<b>74,974</b>	<b>66,586</b>	<b>64,461</b>
Interest paid	4,055	7,005	18,171	20,482	26,711
Interest received	106	119	356	442	841
Income taxes paid	1,403	11,311	29,562	23,271	26,590

# Segment Report

as of September 30, 2024

	Segment AIS Ambulatory Information Systems		Segment HIS Hospital Information Systems		Segment PCS Pharmacy Information Systems		All other segments		Consolidation		CGM Group	
	2024	2023*	2024	2023	2024	2023	2024	2023*	2024	2023*	2024	2023
KEUR	01.01 - 30.09.	01.01 - 30.09.	01.01 - 30.09.	01.01 - 30.09.	01.01 - 30.09.	01.01 - 30.09.	01.01 - 30.09.	01.01 - 30.09.	01.01 - 30.09.	01.01 - 30.09.	01.01 - 30.09.	01.01 - 30.09.
Revenues to third parties	510,758	548,403	232,487	228,848	102,032	103,474	20	14	0	0	845,297	880,739
<b>One-Time Revenues</b>	<b>115,897</b>	<b>169,366</b>	<b>62,879</b>	<b>73,714</b>	<b>29,587</b>	<b>34,821</b>	<b>20</b>	<b>14</b>	<b>0</b>	<b>0</b>	<b>208,383</b>	<b>277,915</b>
<b>Recurring Revenues</b>	<b>394,861</b>	<b>379,037</b>	<b>169,608</b>	<b>155,134</b>	<b>72,445</b>	<b>68,653</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>636,914</b>	<b>602,824</b>
Recurring revenue share in %	77 %	69 %	73 %	68 %	71 %	66 %					75 %	68 %
Revenues between segments	9,004	9,418	4,373	4,183	2,540	3,384	10,709	7,971	-26,626	-24,956	0	0
<b>Segment Revenues</b>	<b>519,762</b>	<b>557,821</b>	<b>236,860</b>	<b>233,031</b>	<b>104,572</b>	<b>106,858</b>	<b>10,729</b>	<b>7,985</b>	<b>-26,626</b>	<b>-24,956</b>	<b>845,297</b>	<b>880,739</b>
Capitalized inhouse services	8,801	12,281	10,342	10,777	5,153	4,323	0	0	0	0	24,296	27,381
Other income	14,296	7,700	8,524	5,261	2,897	1,148	60,339	72,221	-64,669	-66,773	21,387	19,557
Expenses for goods and services purchased	-107,570	-112,316	-48,341	-39,336	-26,217	-27,740	-3,572	-4,227	26,867	24,513	-158,833	-159,106
Personnel costs	-212,297	-218,765	-133,067	-129,652	-33,408	-35,163	-38,850	-37,892	647	318	-416,975	-421,154
Other expenses	-97,032	-105,624	-47,511	-54,713	-15,796	-15,200	-48,629	-44,104	63,781	66,898	-145,187	-152,743
<b>EBITDA</b>	<b>125,960</b>	<b>141,097</b>	<b>26,807</b>	<b>25,368</b>	<b>37,201</b>	<b>34,226</b>	<b>-19,983</b>	<b>-6,017</b>	<b>0</b>	<b>0</b>	<b>169,985</b>	<b>194,674</b>
in % of revenues	24.7 %	25.7 %	11.5 %	11.1 %	36.5 %	33.1 %					20.1 %	22.1 %

\* In 2024, the prior operating segment Consumer & Health Management Systems (CHS) was integrated into the Ambulatory Information Systems Segment (AIS), and some minor profit centers were based on the current structure.

# ADDITIONAL INFORMATION

---

## Financial calendar

Date	Event
March 6, 2025	Annual Report 2024
April 30, 2025	Quarterly Statement Q1 2025
May 14, 2025	Annual General Meeting
July 31, 2025	Interim Report Q2 2025
October 29, 2025	Quarterly Statement Q3 2025

## Contact information

CompuGroup Medical SE & Co. KGaA

Investor Relations

Maria Trost 21

56070 Koblenz

E-Mail: [investor@cgm.com](mailto:investor@cgm.com)

[www.cgm.com](http://www.cgm.com)



**CompuGroup Medical SE & Co. KGaA**

Maria Trost 21  
56070 Koblenz  
Germany

**[www.cgm.com](http://www.cgm.com)**